This complete inactivation is reflected in the potent antitumor activity demonstrated by palazestrant in preclinical xenograft models of both ESR1 wild-type and mutated human breast cancers, where palazestrant treatment resulted in greater tumor shrinkage compared with other endocrine therapies such as fulvestrant and tamoxifen [16–18]. The gene discussed is ESR1; the disease is breast cancer.